New HIV drug Lenacapavir could be manufactured for as little as $40, potentially revolutionizing HIV treatment.
- A new HIV drug, Lenacapavir, developed by Gilead has shown promise in preventing HIV infection, with a two-year injection cycle making administration easier than daily pills.
- The drug currently costs over $40,000 per person annually, but research suggests it could be manufactured for as little as $40, potentially shutting down HIV transmission by targeting high-risk populations.
- The cost estimate was based on production volumes equal to treating 10 million people, suggesting significant potential for cost reduction if generics are allowed.
- UNAIDS chief called on Gilead to make the drug more accessible by opening it up to generic versions in low- and middle-income nations, emphasizing the opportunity to save lives worldwide.
- The firm has not disclosed pricing in developing countries or which nations could eventually access generic versions of the drug.
Source link
HIV/AIDS, Infectious Diseases, Pharmacists, Public Health & Prevention